Axatilimab
- Generic Name
- Axatilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2155851-88-8
- Unique Ingredient Identifier
- R96Z451BMC
- Background
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06713590
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 49
- Registration Number
- NCT06663722
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
- Conditions
- Atypical Chronic Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic/Myeloproliferative NeoplasmRefractory Myeloproliferative NeoplasmChronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative NeoplasmRecurrent Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 52
- Registration Number
- NCT06523556
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT06388564
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic, Los Angeles, California, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT06320405
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 135
- Registration Number
- NCT06132256
- Locations
- 🇦🇺
Mackay Hospital & Health Service, West Mackay, Queensland, Australia
🇧🇪OLV Hospital Aalst, Aalst, Oost-Vlaanderen, Belgium
🇧🇪AZ Groeninge, Kortrijk, West-Vlaanderen, Belgium
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 9
- Registration Number
- NCT05723055
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)
- Conditions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05544032
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Stephen Shiao
- Target Recruit Count
- 35
- Registration Number
- NCT05491226
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 241
- Registration Number
- NCT04710576
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.